Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications

B Ostadal1, P Ostadal

  • 1Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

Insights

Ischaemic heart disease (IHD) risk differs between sexes, with women experiencing increased incidence post-menopause. Understanding these sex-specific differences is crucial for developing targeted therapies to improve outcomes for women with IHD.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Sex Differences in Medicine

Background:

  • Ischaemic heart disease (IHD) is a leading cause of mortality globally.
  • Premenopausal women exhibit lower IHD risk than men, with incidence rising post-menopause, suggesting hormonal influence.
  • Female sex is associated with improved cardiac remodeling following ischaemia/reperfusion injury.

Purpose of the Study:

  • To explore the complex sex-related differences in cardiac tolerance to ischaemia.
  • To investigate the role of sex hormones, particularly oestrogens, in these differences.
  • To highlight the need for female-specific therapeutic strategies in IHD management.

Main Methods:

  • Review of epidemiological studies on IHD incidence and sex differences.
  • Analysis of experimental data on sex-specific cardiac responses to ischaemia/reperfusion.
  • Examination of clinical trial outcomes regarding oestrogen replacement therapy.

Main Results:

  • Oestrogen levels significantly influence IHD risk, with declining levels post-menopause correlating with increased incidence.
  • While oestrogen may offer protection, clinical trials indicate potential harm with hormone replacement therapy in postmenopausal women.
  • Sex-related disparities exist in the management and outcomes of acute coronary syndrome in women.

Conclusions:

  • The mechanisms underlying sex differences in cardiac ischaemic tolerance are complex, involving both genomic and non-genomic effects of sex hormones.
  • Current therapeutic strategies for IHD may not be optimal for women due to unaddressed sex-specific factors.
  • Urgent research is needed to develop personalized, evidence-based treatments for women to reduce IHD mortality and improve quality of life.